{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:34:01Z","timestamp":1755225241032,"version":"3.43.0"},"reference-count":9,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ectopic expression of PTH in nonmetastatic prostate cancer is a rare occurrence. We present a case of a 60-year-old Chinese man who initially presented with hyperparathyroidism, PTH 80.1\u2005pg\/mL (SI: 8.5\u2005pmol\/L) (reference range, 8.5-58.5\u2005pg\/mL [SI: 0.9-6.2\u2005pmol\/L]), hypophosphatemia, 1.95\u2005mg\/dL (SI: 0.63\u2005mmol\/L) (reference range, 2.91-4.64\u2005mg\/dL [SI: 0.94-1.5\u2005mmol\/L]) and normal calcium levels, 2.27\u2005mmol\/L (SI 9.08\u2005mg\/dL) (reference range, 2.1-2.6\u2005mmol\/L [SI: 8.4-10.4\u2005mg\/dL]). Two years later, he was diagnosed with prostate adenocarcinoma. A whole-body bone scan ruled out osteoblastic metastases. Notably, the patient exhibited elevated urinary calcium excretion, 304.6\u2005mg\/day (SI: 7.6\u2005mmol\/day) (reference range, 33.2-272.6\u2005mg\/day [SI: 0.82-6.74\u2005mmol\/day]) and indeterminate urinary fractional calcium excretion (1.79%). A Technetium-99 sestamibi scan did not identify any hyperfunctioning parathyroid adenoma. Following treatment for prostate cancer, both hyperparathyroidism and hypophosphatemia resolved. Immunostaining of prostate cancer tissue revealed ectopic PTH expression. This case highlights a rare cause of hyperparathyroidism due to ectopic PTH secretion in prostate cancer, adding to known etiologies such as osteoblastic metastases, vitamin D deficiency, oncogenic osteomalacia, renal insufficiency, and primary hyperparathyroidism. Recognizing ectopic PTH expression is crucial for managing prostate cancer patients presenting with hyperparathyroidism.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf158","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:50:45Z","timestamp":1752767445000},"source":"Crossref","is-referenced-by-count":0,"title":["Ectopic Parathyroid Hormone Expression in Nonmetastatic Prostate Cancer"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-4886","authenticated-orcid":false,"given":"Suresh","family":"Rama Chandran","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Singapore General Hospital , Singapore 169608, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7282-6440","authenticated-orcid":false,"given":"Yongcheng Benjamin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Division of Pathology, Singapore General Hospital ,","place":["Singapore 169608, Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"3","key":"2025081304270484900_luaf158-B1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1055-9965.EPI-07-2747","article-title":"Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases","volume":"17","author":"Schwartz","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2025081304270484900_luaf158-B2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<183::AID-PROS6>3.0.CO;2-N","article-title":"Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis","volume":"30","author":"Ritchie","year":"1997","journal-title":"Prostate"},{"issue":"3","key":"2025081304270484900_luaf158-B3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7326\/0003-4819-92-3-351","article-title":"Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration","volume":"92","author":"Marx","year":"1980","journal-title":"Ann Intern Med"},{"issue":"17","key":"2025081304270484900_luaf158-B4","doi-asserted-by":"crossref","first-page":"e37934","DOI":"10.1097\/MD.0000000000037934","article-title":"Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients","volume":"103","author":"Zhao","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2025081304270484900_luaf158-B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1634\/theoncologist.2011-0448","article-title":"Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration","volume":"17","author":"Berruti","year":"2012","journal-title":"Oncologist"},{"issue":"6","key":"2025081304270484900_luaf158-B6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"2025081304270484900_luaf158-B7","first-page":"100","article-title":"Effect of vitamin D supplementation in prostate cancer: a systematic review of randomized control trials","volume":"88","author":"Petrou","year":"2019","journal-title":"Int J Vitam Nutr Res"},{"issue":"2","key":"2025081304270484900_luaf158-B8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12020-017-1351-0","article-title":"Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study","volume":"59","author":"Minisola","year":"2018","journal-title":"Endocrine"},{"issue":"7","key":"2025081304270484900_luaf158-B9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/RLU.0000000000003064","article-title":"Metastatic parathyroid hormone-secreting prostate adenocarcinoma mimicking ectopic parathyroid adenoma demonstrated on 99mTc-MIBI image","volume":"45","author":"Chen","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf158\/63790040\/luaf158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf158\/63790040\/luaf158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:27:10Z","timestamp":1755073630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf158\/8205583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf158","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"luaf158"}}